Skip to main content

PROTEINAS SCAFFOLD COMO MODULADORES DE LA RESISTENCIA A INHIBIDORES DE LA RUTA RAS-ERK EN MELANOMA

SAF2015-63638-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Defined spatiotemporal features of RAS-ERK signals dictate cell fate in MCF-7 mammary epithelial cells

  • Herrero, Ana
  • Casar, Berta
  • Colón-Bolea, Paula
  • Agudo-Ibáñez, Lorena
  • Crespo, Piero
Signals conveyed through the RAS-ERK pathway are essential for the determination of cell fate. It is well established that signal variability is achieved in the different microenvironments in which signals unfold. It is also known that signal duration is critical for decisions concerning cell commitment. However, it is unclear how RAS-ERK signals integrate time and space in order to elicit a given biological response. To investigate this, we used MCF-7 cells, in which EGF-induced transient ERK activation triggers proliferation, whereas sustained ERK activation in response to heregulin leads to adipocytic differentiation. We found that both proliferative and differentiating signals emanate exclusively from plasma membrane- disordered microdomains. Of interest, the EGF signal can be transformed into a differentiating stimulus by HRAS overexpression, which prolongs ERK activation, but only if HRAS localizes at disordered membrane. On the other hand, HRAS signals emanating from the Golgi complex induce apoptosis and can prevent heregulin-induced differentiation. Our results indicate that within the same cellular context, RAS can exert different, even antagonistic, effects, depending on its sublocalization. Thus cell destiny is defined by the ability of a stimulus to activate RAS at the appropriate sublocalization for an adequate period while avoiding switching on opposing RAS signals., P.C.’s lab is supported by the Spanish Ministry of Economy–Fondos FEDER (Grant BFU2011-23807) and SAF-2015 63638R (MINECO/FERDER, UE), the Red Temática de Investigación Cooperativa en Cáncer (RD/12/0036/0033), and the Asociación Española Contra el Cáncer (Grant GCB141423113), Spanish Ministry of Health. B.C. is a Consejo Superior de Investigaciones Científicas JAE-Doc Program Postdoctoral Fellow, supported by the European Social Fund. A.H. has been supported by funding from the European Union Seventh Framework Programme (FP7/2007-2013) PRIMES project under Grant Agreement FP7-HEALTH-2011-278568., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An Integrated Global Analysis of Compartmentalized HRAS Signaling

  • Santra, Tapesh
  • Herrero, Ana
  • Rodríguez, Javier
  • Kriegsheim, Alexvon
  • Iglesias-Martinez, Luis F.
  • Schwarzl, Thomas
  • Higgins, Des
  • Aye, Thin-Thin
  • Heck, Albert J. R.
  • Calvo, Fernando
  • Agudo-Ibáñez, Lorena
  • Crespo, Piero
  • Matallanas, David
  • Kolch, Walter
Modern omics technologies allow us to obtain global information on different types of biological networks. However, integrating these different types of analyses into a coherent framework for a comprehensive biological interpretation remains challenging. Here, we present a conceptual framework that integrates protein interaction, phosphoproteomics, and transcriptomics data. Applying this method to analyze HRAS signaling from different subcellular compartments shows that spatially defined networks contribute specific functions to HRAS signaling. Changes in HRAS protein interactions at different sites lead to different kinase activation patterns that differentially regulate gene transcription. HRASmediated signaling is the strongest from the cell membrane, but it regulates the largest number of genes from the endoplasmic reticulum. The integrated networks provide a topologically and functionally resolved view of HRAS signaling. They reveal distinct HRAS functions including the control of cell migration from the endoplasmic reticulum and TP53-dependent cell survival when signaling from the Golgi apparatus., This work was supported by the Science Foundation Ireland grants 06/CE/B1129, 14/IA/2395, and 15_CDA_3495; Irish Cancer Society BREAST-PREDICT grant CCRC13GAL; and by the European Union FP7 grant 278568 “PRIME-XS.” T.-T.A. and A.J.R.H. were supported by the Roadmap Initiative Proteins@Work (184.032.201) funded by the Netherlands Organisation for Scientific Research (NWO). P.C. was supported by grant SAF-2015 63638R (MINECO/FEDER, UE); by Centro de Investigación Biomédica en Red de Cáncer; and by Asociación Española Contra el Cáncer (AECC), grant GCB141423113.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer

  • Zaballos, Miguel A.
  • Acuña-Ruiz, Adrián
  • Morante, Marta
  • Crespo, Piero
  • Santisteban, Pilar
Thyroid cancer is mostly an ERK-driven carcinoma, as up to 70% of thyroid carcinomas are caused by mutations that activate the RAS/ERK mitogenic signaling pathway. The incidence of thyroid cancer has been steadily increasing for the last four decades; yet, there is still no effective treatment for advanced thyroid carcinomas. Current research efforts are focused on impairing ERK signaling with small-molecule inhibitors, mainly at the level of BRAF and MEK. However, despite initial promising results in animal models, the clinical success of these inhibitors has been limited by the emergence of tumor resistance and relapse. The RAS/ERK pathway is an extremely complex signaling cascade with multiple points of control, offering many potential therapeutic targets: from the modulatory proteins regulating the activation state of RAS proteins to the scaffolding proteins of the pathway that provide spatial specificity to the signals, and finally, the negative feedbacks and phosphatases responsible for inactivating the pathway. The aim of this review is to give an overview of the biology of RAS/ERK regulators in human cancer highlighting relevant information on thyroid cancer and future areas of research., The Santisteban and Crespo Laboratories are supported jointly by grants from Asociación Española Contra el Cancer (AECC; GCB141423113) and CIBERONC from the Instituto de Salud Carlos III (ISCIII). In addition, the authors acknowledge the following funding support: SAF2016-75531-R (MINECO/FEDER, UE); B2017/BMD-3724 Tironet2 (Comunidad de Madrid) and RTICC from ISCIII (RD/12/0036/0030) (granted to P S); and SAF-2015 63638R (MINECO/FEDER, UE) and RTICC (RD/12/0036/0033) (granted to P C).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RAC1 induces nuclear alterations through the LINC complex to enhance melanoma invasiveness

  • Colón-Bolea, Paula
  • García-Gómez, Rocío
  • Shackleton, Sue
  • Crespo, Piero
  • Bustelo, Xosé R.
  • Casar, Berta
© 2020 Colón-Bolea et al., RHO GTPases are key regulators of the cytoskeletal architecture, which impact a broad range of biological processes in malignant cells including motility, invasion, and metastasis, thereby affecting tumor progression. One of the constraints during cell migration is the diameter of the pores through which cells pass. In this respect, the size and shape of the nucleus pose a major limitation. Therefore, enhanced nuclear plasticity can promote cell migration. Nuclear morphology is determined in part through the cytoskeleton, which connects to the nucleoskeleton through the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex. Here, we unravel the role of RAC1 as an orchestrator of nuclear morphology in melanoma cells. We demonstrate that activated RAC1 promotes nuclear alterations through its effector PAK1 and the tubulin cytoskeleton, thereby enhancing migration and intravasation of melanoma cells. Disruption of the LINC complex prevented RAC1-induced nuclear alterations and the invasive properties of melanoma cells. Thus, RAC1 induces nuclear morphology alterations through microtubules and the LINC complex to promote an invasive phenotype in melanoma cells., B.C.’s laboratory is supported by a Retos Jóvenes Investigadores grant SAF2015-73364-JIN Ministerio de Ciencia, Innovación y Universidades (MICIU/AEI/FEDER, UE), a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)—MCIU, and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I). P.C is supported by grant SAF-2015 63638R (MINECO/FEDER, UE); by Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC), RD/12/0036/0033, and by Asociación Española Contra el Cáncer (AECC) grant GCB141423113. X.R.B. is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), MINECO (SAF2015-64556-R, RD12/0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and AECC (GC16173472GARC). Spanish funding to B.C., P.C., and X.R.B. is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation

  • Casar, Berta
  • Badrock, Andrew P.
  • Jiménez, Iñaki
  • Arozarena, Imanol
  • Colón-Bolea, Paula
  • Lorenzo-Martín, L. Francisco
  • Barinaga-Rementería, Irene
  • Barriuso, Jorge
  • Cappitelli, Vincenzo
  • Donoghue, Daniel J.
  • Bustelo, Xosé R.
  • Hurlstone, Adam
  • Crespo, Piero
© The Author(s) 2018., RAS GTPases are frequently mutated in human cancer. H- and NRAS isoforms are distributed over both plasma-membrane and endomembranes, including the Golgi complex, but how this organizational context contributes to cellular transformation is unknown. Here we show that RAS at the Golgi is selectively activated by apoptogenic stimuli and antagonizes cell survival by suppressing ERK activity through the induction of PTPRκ, which targets CRAF for dephosphorylation. Consistently, in contrast to what occurs at the plasma-membrane, RAS at the Golgi cannot induce melanoma in zebrafish. Inactivation of PTPRκ, which occurs frequently in human melanoma, often coincident with TP53 inactivation, accelerates RAS-ERK pathway-driven melanomagenesis in zebrafish. Likewise, tp53 disruption in zebrafish facilitates oncogenesis driven by RAS from the Golgi complex. Thus, RAS oncogenic potential is strictly dependent on its sublocalization, with Golgi complex-located RAS antagonizing tumor development., We are grateful to Drs: Ignacio Rubio, Yardena Samuels, Mariano Barbacid and Javier León for providing reagents; and Alicia Noriega, Sandra Zunzunegui y Victor Campa for technical support. Crespo laboratory is supported by grant SAF-2015 63638R (MINECO/ FEDER, UE); by Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033 and by Asociación Española Contra el Cáncer (AECC), grant GCB141423113. Work in the Hurlstone laboratory was unded by a grant from the European Research Council (ERC-2011-StG-282059 PROMINENT). B.C. is supported by a Retos Jóvenes Investigadores grant SAF2015-73364-JIN (AEI/FEDER, UE) and a grant from Fundación Francisco Cobos. X.R.B. is supported by grants from the CastillaLeón Government (BIO/SA01/15, CSI049U16), MINECO (SAF2015-64556-R, RD12/ 0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, andAECC (GC16173472GARC). Spanish funding to P.C., B.C., and X.R.B. is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RAS GTPase-dependent pathways in developmental diseases: old guys, new lads, and current challenges

  • Bustelo, Xosé R.
  • Crespo, Piero
  • Fernández-Pisonero, Isabel
  • Rodríguez-Fdez, Sonia
Deregulated RAS signaling is associated with increasing numbers of congenital diseases usually referred to as RASopathies. The spectrum of genes and mutant alleles causing these diseases has been significantly expanded in recent years. This progress has triggered new challenges, including the origin and subsequent selection of the mutations driving these diseases, the specific pathobiological programs triggered by those mutations, the type of correlations that exist between the genotype and the clinical features of patients, and the ancillary genetic factors that influence the severity of the disease in patients. These issues also directly impinge on the feasibility of using RAS pathway drugs to treat RASopathy patients. Here, we will review the main developments and pending challenges in this research topic., The authors wish to apologize to scientists who have not been cited in this work due to space constraints. XRB work is supported by grants from the Castilla-León Government (CSI049U16), Spanish Ministry of Economy and Competitiveness (SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and Spanish Society against Cancer (GC16173472GARC). PC work is supported by grants from both the Spanish Ministry of Economy and Competitiveness (SAF-2015 63638R) and the Spanish Society against Cancer (GCB141423113). Funding from Spanish national and regional governments to both XRB and PC is partially contributed by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The RAS-ERK pathway: A route for couples

  • Santos de Dios, Eugenio
  • Crespo, Piero
Data accumulated over more than three decades demonstrate that the assembly of macrocomplexes, mainly of dimers, is widespread among the members of the different tiers that constitute the RAS-ERK pathway. In this issue of Science Signaling, Yuan et al. report that MEK1 homodimerization is necessary for signal transduction through the RAF-ERK pathway and that cancer-related MEK1 mutations confer enhanced dimerization and resistance to MEK inhibitors. These findings endorse interference with RAS-ERK pathway–component dimerization as a potential therapeutic strategy in cancer patients., Work in the Santos and Crespo laboratories is supported by grant SAF-2015 63638R (MINECO/FEDER, UE), Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC) (RD/12/0036/0033), Asociación Española Contra el Cáncer (AECC) (GCB141423113) (to P.C.), and grants FIS PI16/02137 and RD12/0036/0001 from ISCIII (MINECO) and SA043U16 (UIC 076) from JCyL (to E.S.). CIBERONC is cofinanced by FEDER funds. C
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ras and Rap Signal Bidirectional Synaptic Plasticity via Distinct Subcellular Microdomains

  • Zhang, Lei
  • Zhang, Peng
  • Wang, Guangfu
  • Zhang, Huaye
  • Zhang, Yajun
  • Yu, Yilin
  • Zhang, Mingxu
  • Xiao, Jian
  • Crespo, Piero
  • Hell, Johannes W.
  • Lin, Li
  • Huganir, Richard L.
  • Zhu, J. Julius
How signaling molecules achieve signal diversity and specificity is a long-standing cell biology question. Here we report the development of a targeted delivery method that permits specific expression of homologous Ras-family small GTPases (i.e., Ras, Rap2, and Rap1) in different subcellular microdomains, including the endoplasmic reticulum, lipid rafts, bulk membrane, lysosomes, and Golgi complex, in rodent hippocampal CA1 neurons. The microdomain-targeted delivery, combined with multicolor fluorescence protein tagging and high-resolution dual-quintuple simultaneous patch-clamp recordings, allows systematic analysis of microdomain-specific signaling. The analysis shows that Ras signals long-term potentiation via endoplasmic reticulum PI3K and lipid raft ERK, whereas Rap2 and Rap1 signal depotentiation and long-term depression via bulk membrane JNK and lysosome p38MAPK, respectively. These results establish an effective subcellular microdomain-specific targeted delivery method and unveil subcellular microdomain-specific signaling as the mechanism for homologous Ras and Rap to achieve signal diversity and specificity to control multiple forms of synaptic plasticity., This study was supported in part by a Virginia Center on Aging postdoctoral ARDRAF award (to L.Z.); Epilepsy Foundation Postdoctoral Fellowship 310443 (to G.W.); MINECO/FEDER-UE grant SAF-2015-63638R, RTICC grant RD-12-0036-0033, and AECC grant GCB141423113 (to P.C.); National Natural Science Foundation of China grants NSFC81722028 (to J.X.) and NSFC81771284 (to L.L.); HHMI (to R.L.H.); NIH grants NS036715 (to R.L.H.), NS065183 and NS089578 (to H.Z.), NS078792 (to J.W.H.), and NS053570, NS091452, NS094980, NS092548, and NS104670 (to J.J.Z.). J.J.Z. is a Radboud Professor and Sir Yue-Kong Pao Chair Professor.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer

  • Moreno, Thaidy
  • Monterde, Beatriz
  • González-Silva, Laura
  • Betancor-Fernández, Isabel
  • Revilla, Carlos
  • Agraz-Doblas, Antonio
  • Freire, Javier
  • Isidro, Pablo
  • Quevedo, Laura
  • Blanco, Rosa
  • Montes-Moreno, Santiago
  • Cereceda, Laura
  • Astudillo, Aurora
  • Casar, Berta
  • Crespo, Piero
  • Morales Torres, Cristina
  • Scaffidi, Paola
  • Gómez-Román, Javier
  • Salido, Eduardo
  • Varela, Ignacio
The survival rate in lung cancer remains stubbornly low and there is an urgent need for the identification of new therapeutic targets. In the last decade, several members of the SWI/SNF chromatin remodeling complexes have been described altered in different tumor types. Nevertheless, the precise mechanisms of their impact on cancer progression, as well as the application of this knowledge to cancer patient management are largely unknown. In this study, we performed targeted sequencing of a cohort of lung cancer patients on genes involved in chromatin structure. In addition, we studied at the protein level the expression of these genes in cancer samples and performed functional experiments to identify the molecular mechanisms linking alterations of chromatin remodeling genes and tumor development. Remarkably, we found that 20% of lung cancer patients show ARID2 protein loss, partially explained by the presence of ARID2 mutations. In addition, we showed that ARID2 deficiency provokes profound chromatin structural changes altering cell transcriptional programs, which bolsters the proliferative and metastatic potential of the cells both in vitro and in vivo. Moreover, we demonstrated that ARID2 deficiency impairs DNA repair, enhancing the sensitivity of the cells to DNA-damaging agents. Our findings support that ARID2 is a bona fide tumor suppressor gene in lung cancer that may be exploited therapeutically., IV is supported by SAF2012-31627 and SAF2016-76758-R grants from the Spanish Ministerio de Economía y Competitividad (MINECO), by a Fundación Ramón Areces grant and by ERC2014-StG637904 grant from the European Research Council. IV has been awardee of the Programa Ramón y Cajal (MINECO, Spain). TM has been awardee of the Ayudas para la contratación de investigadores predoctorales (MINECO, Spain). BM is awardee of the Ayudas para la formación de profesorado universitario (FPU, Ministerio de Educación y Formación Profesional, Spain). PC laboratory is supported by grant SAF-2015-63638R (MINECO/FEDER, UE); by Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) and by Asociación Española Contra el Cáncer (AECC), grant GCB141423113. BC has been supported by a Retos Jóvenes Investigadores grant SAF-2015-73364-JIN (AEI/FEDER, UE) and a grant from Fundación Francisco Cobos. PS is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001152) and the UK Medical Research Council (FC001152). HUCA/IUOPA is jointly financed by Servicio de Salud del Principado de Asturias, Instituto de Salud Carlos III, and Fundación Bancaria Cajastur. This research was funded in part by the Wellcome Trust [FC001152].